The global drug delivery devices market size was estimated to be USD 324.12 billion in 2023 and is expected to reach at USD 747.3 billion by 2033 with a CAGR of 7.89% during the forecast period 2023-2033. Increasing focus on development of advanced technology for effective drug delivery, growing demand for novel drug delivery devices, rising research & development activities, surge in adoption of drug delivery devices in home-care settings, increasing technological advancements, growing product approvals by regulatory bodies, and rising introduction of new products are some of the key factors boosting the market growth.
Rising introduction of new products is predicted to boost the market growth during the forecast period. For instance, in May 2021, Phillips-Medisize has introduced the Aria Smart Autoinjector platform, revolutionizing the digital drug-delivery device market by providing opportunities for innovation, distinctiveness, and eco-friendliness. The device boasts cutting-edge features like a modular drug delivery platform, accommodating various drug formulations and viscosities, and incorporating Bluetooth for seamless connectivity to smartphones, tablets, and mobile apps.
By Route of Administration, Inhalation was the highest revenue-grossing segment in the global drug delivery devices market in 2022 owing to the increasing prevalence of asthma & Chronic Obstructive Pulmonary Disease (COPD) and rising technological advancements in inhalation delivery devices such as nebulizers & inhalers. Additionally, Topical is predicted to grow at fastest CAGR during the forecast period owing to the rising development of novel products and increasing launch of new products. For instance, in December 2020, Agile Therapeutics, Inc., a company specializing in women's healthcare, has officially released Twirla (levonorgestrel and ethinyl estradiol) transdermal system, an innovative contraceptive patch that is non-daily and non-invasive.
By Application, Diabetes was the highest revenue-grossing segment in the global drug delivery devices market in 2022 owing to the rising prevalence of diabetes, increasing technological advancements, and growing introduction of advanced drug delivery devices. Additionally, Central Nervous System (CNS) disorders is predicted to grow at fastest CAGR during the forecast period owing to the growing incidence of neurological disorders such as Parkinson’s disorder, Alzheimer’s disease, Hunter’s syndrome, and brain tumor and rising launch of innovative products by market players. For instance, in June 2020, Vektor Pharma has unveiled a generic edition of the Neupro patch (rotigotine), a transdermal patch prescribed for alleviating Parkinson's disease symptoms.
By End-user, Hospitals was the highest revenue-grossing segment in the global drug delivery devices market in 2022 owing to the increasing prevalence of chronic disorders such as cancer, diabetes, & neurological disorders, surge in number of patients visiting hospitals for effective treatment, and rising technological advancements. Additionally, Diagnostic centers is predicted to grow at fastest CAGR during the forecast period owing to the increasing focus on development & adoption of novel drug delivery devices for delivering drugs accurately, rising initiatives by market players such as new product launches, and growing product approvals by regulatory bodies. For instance, in March 2022, The U.S. FDA granted approval to Vitaris, Inc. in collaboration with Kindeva Drug Delivery L.P. for Breyna, a drug-device inhalation aerosol combination designed to aid patients with asthma and COPD.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising adoption of drug delivery devices, surge in prevalence of chronic diseases, growing awareness regarding the advantages of drug delivery devices, increasing presence of major players, rising product approval, and surge in launch of transdermal patches. For instance, in March 2022, The US FDA granted approval to Corium for Adlarity, a treatment aimed at patients with Alzheimer's, experiencing mild, moderate, or severe dementia. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of advanced drug delivery devices, growing technological advancements, and rising launch of novel products within the region. For instance, in June 2022, Gufic Biosciences Ltd has made the Dual Chamber Bags drug delivery system available in India at budget-friendly prices, marking its debut in the market.
Rising introduction of new products is predicted to boost the market growth during the forecast period. For instance, in May 2021, Phillips-Medisize has introduced the Aria Smart Autoinjector platform, revolutionizing the digital drug-delivery device market by providing opportunities for innovation, distinctiveness, and eco-friendliness. The device boasts cutting-edge features like a modular drug delivery platform, accommodating various drug formulations and viscosities, and incorporating Bluetooth for seamless connectivity to smartphones, tablets, and mobile apps.
By Route of Administration, Inhalation was the highest revenue-grossing segment in the global drug delivery devices market in 2022 owing to the increasing prevalence of asthma & Chronic Obstructive Pulmonary Disease (COPD) and rising technological advancements in inhalation delivery devices such as nebulizers & inhalers. Additionally, Topical is predicted to grow at fastest CAGR during the forecast period owing to the rising development of novel products and increasing launch of new products. For instance, in December 2020, Agile Therapeutics, Inc., a company specializing in women's healthcare, has officially released Twirla (levonorgestrel and ethinyl estradiol) transdermal system, an innovative contraceptive patch that is non-daily and non-invasive.
By Application, Diabetes was the highest revenue-grossing segment in the global drug delivery devices market in 2022 owing to the rising prevalence of diabetes, increasing technological advancements, and growing introduction of advanced drug delivery devices. Additionally, Central Nervous System (CNS) disorders is predicted to grow at fastest CAGR during the forecast period owing to the growing incidence of neurological disorders such as Parkinson’s disorder, Alzheimer’s disease, Hunter’s syndrome, and brain tumor and rising launch of innovative products by market players. For instance, in June 2020, Vektor Pharma has unveiled a generic edition of the Neupro patch (rotigotine), a transdermal patch prescribed for alleviating Parkinson's disease symptoms.
By End-user, Hospitals was the highest revenue-grossing segment in the global drug delivery devices market in 2022 owing to the increasing prevalence of chronic disorders such as cancer, diabetes, & neurological disorders, surge in number of patients visiting hospitals for effective treatment, and rising technological advancements. Additionally, Diagnostic centers is predicted to grow at fastest CAGR during the forecast period owing to the increasing focus on development & adoption of novel drug delivery devices for delivering drugs accurately, rising initiatives by market players such as new product launches, and growing product approvals by regulatory bodies. For instance, in March 2022, The U.S. FDA granted approval to Vitaris, Inc. in collaboration with Kindeva Drug Delivery L.P. for Breyna, a drug-device inhalation aerosol combination designed to aid patients with asthma and COPD.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising adoption of drug delivery devices, surge in prevalence of chronic diseases, growing awareness regarding the advantages of drug delivery devices, increasing presence of major players, rising product approval, and surge in launch of transdermal patches. For instance, in March 2022, The US FDA granted approval to Corium for Adlarity, a treatment aimed at patients with Alzheimer's, experiencing mild, moderate, or severe dementia. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of advanced drug delivery devices, growing technological advancements, and rising launch of novel products within the region. For instance, in June 2022, Gufic Biosciences Ltd has made the Dual Chamber Bags drug delivery system available in India at budget-friendly prices, marking its debut in the market.
Segmentation: Drug Delivery Devices Market Report 2022 - 2033
Drug Delivery Devices Market Analysis & Forecast by Route of Administration 2022 - 2033 (Revenue USD Bn)
- Injectable
- Inhalation
- Oral
- Topical
- Nasal
- Ocular
- Transdermal
- Others
Drug Delivery Devices Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Diabetes
- Cardiovascular Diseases
- Oncology
- Infectious Diseases
- Respiratory Diseases
- Central Nervous System Disorders
- Autoimmune Diseases
- Others
Drug Delivery Devices Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Diagnostic Centers
- Hospitals
- Home Care Settings
- Ambulatory Surgery Centers/Clinics
- Others
Drug Delivery Devices Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Drug Delivery Devices Market: Route of Administration Estimates & Trend Analysis
8. Drug Delivery Devices Market: Application Estimates & Trend Analysis
9. Drug Delivery Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Drug Delivery Devices Market
12. Europe Global Drug Delivery Devices Market
13. Asia Pacific Global Drug Delivery Devices Market
14. Latin America Global Drug Delivery Devices Market
15. MEA Global Drug Delivery Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Altaris
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson
- Biocorp
- Bayer AG
- Merck KGaA
- Becton
- Dickinson & Company
- Holozymes Inc. (Antares Pharma Inc.)
- West Pharmaceutical Services Inc.
- Elcam Medical
- GlaxoSmithKline PLC
- F Hoffmann-La Roche Ltd
- Molex (Philips Medisize)
- Teva Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 324.12 Billion |
| Forecasted Market Value ( USD | $ 747.3 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
